Achieves or exceeds all previously announced full-year 2025 guidance metrics On track to complete proposed acquisition by Nexstar Media Group by the second half of 2026, subject to regulatory approvals and customary closing conditions MCLEAN, Va., March 02, 2026 (GLOBE NEWSWIRE) — TEGNA Inc. (NYSE: TGNA) today announced financial results for the fourth quarter and full-year 2025, ended December 31, 2025. FOURTH QUARTER FINANCIAL HIGHLIGHTS:All Year-Over-Year Comparisons Unless Otherwise Noted:Total company revenue was down 19% from the prior year at $706 million primarily due to lower political advertising revenue, consistent with cyclical even-to-odd year comparisons partially offset by growth in Advertising and Marketing Services (AMS) revenue.  Distribution revenue was slightly lower at $358 million due to subscriber declines,...

– Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 – – Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA – – Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 trial design to be presented at MDA – – Advancing four development candidates for the potential treatment of DMD amenable to skipping of exons 53, 45, 44, and 55 – – Year-end cash of $1.1 billion; reaffirming expected cash runway into Q1 2028 – WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) — Dyne...

~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal A enzyme activity ~ ~ Cash, cash equivalents and current investment securities of approximately $622.5 million as of December 31, 2025 expected to fund operations into the second half of 2029 ~ ~ uniQure to host earnings call at 8:00 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) — uniQure N.V....

Continued strong financial results and cash generation, achieving all 2025 guidance metrics Full year earnings growth; GAAP EPS up 3%, Adjusted EPS up 19% Returned $791 million to shareholders through share repurchases and dividends Multi-year financial framework focused on growth in revenue, earnings, and cash flow BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT), a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S., today reported results for the fourth quarter and full year of 2025. Financial highlights for the fourth quarter and full year are below with variances on a year-over-year basis unless otherwise noted. Results of the former commercial and solar businesses are presented as discontinued operations, except for cash...

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided guidance for the first quarter and full year 2026. HighlightsGrew total revenue 3.7% to $9.8 billion in 2025. GAAP net income was $423.2 million, with EPS of $0.92. Delivered Adjusted EBITDA1 of $2.73 billion in 2025, exceeding guidance, and representing an increase of 11% compared to 2024. Adjusted Net Income grew 15% to $1.045 billion. Adjusted EPS grew 19% to $2.11. Company sets full year 2026 guidance with Adjusted EPS expected to be $2.38. Company completed first phase of enhancements to Great Stirrup Cay, the...

Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024 Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of 2024 Total Company Adjusted EBITDA(1) margins increased by 29 bps to 16.0% in the fourth quarter of 2025 as compared with 15.7% in the fourth quarter...

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three and twelve months ended December 31, 2025. ProductionFourth Quarter 2025Strong quarterly production of 47,178 ounces gold equivalent (“AuEq”)(1) or 44,129 oz gold, 1,940,781 lbs copper and 47,427 oz silver. Cash costs of US$768/oz gold, and all-in sustaining costs (“AISC”) of US$1,619/oz gold (3). Record quarterly ore processed of 186,198 tonnes, a 93% increase from Q4 2024, with a head grade of 8.0 grams per tonne (“g/t”) AuEq, or 7.4 g/t gold, 0.5% copper and 10 g/t silver, with a moderate positive gold and copper grade reconciliation versus the latest independent mineral resource estimate (September 12, 2023 effective date for Kora and Judd). Strong...

Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026 Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and China Additional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J) $62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program $250.0 million non-recourse royalty-backed note financing from Royalty Pharma to provide non-dilutive capital to support the ongoing stock repurchase program, potential strategic...

Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026 Completed enrollment in the Phase 2/3 DRAGON II trial in STGD1 Completed a $402 million underwritten public offering of American Depositary Shares Conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ETSAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its preliminary, unaudited financial results for the fourth...

DALLAS, March 02, 2026 (GLOBE NEWSWIRE) — Kosmos Energy Ltd. (“Kosmos” or the “Company”) (NYSE/LSE: KOS) announced today its financial and operating results for the fourth quarter of 2025. For the quarter, the Company generated a net loss of $377 million, or $0.79 per diluted share. When adjusted for certain items that impact the comparability of results, the Company generated an adjusted net loss(1) of $78 million, or $0.16 per diluted share for the fourth quarter of 2025. FOURTH QUARTER 2025 AND POST QUARTER END HIGHLIGHTSZero lost-time injuries or total recordable injuries in 2025Net Production(2): ~67,900 barrels of oil equivalent per day (boepd), up ~4% versus third quarter 2025, with sales of ~62,900 boepdRevenues: $295 million, or $50.88 per boe (excluding the impact of derivative cash settlements)Production expense:...